Lifestyle

Charles Winn gives the Lowdown on the World’s ‘Fine Wine’ Capital

Published

5 years ago

November 3, 2020

The majority of the world might remain in lockdown amid the ongoing coronavirus pandemic, but for some industries life must continue as normal, such as for ‘fine wine’. Whilst the rest of the world locks down, in Bordeaux – the fine wine capital of the world – producers are hard at work preparing their crops for the next season.

Geography

A port city on the Garonne River in southwestern France, Bordeaux is renowned globally for its famous wine-growing regions. A river runs directly through the region, and on the West side sits Gironde and Garonne. Typically, these regions are known for wines such as Sauvignon. On the East side of the river nestles Dordogne, known primarily for Merlot.

In total, Bordeaux has 57 grape-growing regions making it the biggest wine producer in France. Originally made famous for its popularity with kings, nowadays, Bordeaux and its chateaus are popular tourist attractions.

The Wines

As one of the biggest wine-makers in the world, you might expect Bordeaux to produce a diverse range of different type of wines. However, more than 90% of the wine produced here is actually red, with the region specifically producing Cabernet Sauvignon, Cabernet Franc, Merlot, Petit Verdot, Malbec and Carménère.

Having said this, in 2019 Bordeaux’s regulatory body approved four additional dark grape varieties to add to the list: Marselan, Touriga Nacional, Castets, and Arinarnoa.

Bordeaux’s First Growth wines (the term for a wine made specifically made in Bordeaux) are made by blending 70% Cabernet Sauvignon, 15% Cabernet Franc and 15% Merlot. In contrast, the White Bordeaux is made from Sémillon, Sauvignon Blanc and Muscadelle.

The History

Bordeaux’s wine-making history stretches back over many centuries. In 1855, the Association of Bordeaux Wine Merchants established official classification and certification of the wines after Emperor Napoleon III requested that they do so.

Ranking the wines from First Growths to Fifth Growths, the merchants evaluated market prices based on an evaluation of the previous years. They noticed that red wines which made the list came from the Médoc region, except for one: Château Haut-Brion from Graves.

Since this original classification in 1855, there have only been two changes. In 1856, Château Cantemerle was added as a Fifth Growth and in 1973, Château Mouton Rothschild was promoted from Second Growth to the elite First Growth classification. The latter change is a wine much loved and highly ranked by Charles Winn and its customers.

Château Margaux

Global flavour

It didn’t take long for the popularity of Bordeaux wine to grow all over the world. After King Henry II’s marriage to Eleanor of Aquitaine in 1152, an interest in wine from the Bordeaux region was prompted in England.

The marriage established the province of Aquitaine within France and England, and a new dark rosé wine was created, called ‘Claret’. This wine soon became the most common wine to be exported to Britain.

After the battle of Castillion in 1453, the Aquitaine region returned to the French. Since then, the word ‘Claret’ became anglicised and is still widely used today, due to the global popularity of the wine.

The exterior of the château

Lifestyle

Kat Marie Alvarez: Where Innovation Meets Regulation

Published

11 hours ago

January 23, 2026

Michelle Langton

Regulation is often thought of as a limitation, yet in healthcare, it also serves as a foundation for building models that endure. For Kat Marie Alvarez, Founder and CEO of KATALYST & CO, the framework of rules established by agencies like CMS (Centers for Medicare and Medicaid) and the OIG ( office of the Inspector General) create opportunities to design systems that are compliant, ethical, and transformative. Her approach demonstrates that regulation can be a platform for innovation when it is interpreted with both technical rigor and vision.

Kat’s 25-year career reflects this philosophy. A former nurse who advanced into executive leadership and strategy, she has led $2.7B+ P&L operations, advised on over $5B in healthcare transactions, and guided value based organizations including Innovacare, Cano Health, WellMed, Centene, and Humana through periods of exponential scaling. Her perspective combines clinical, financial, and regulatory experience, giving her a unique ability to design structures that support integrity and accountability while driving measurable outcomes.

Turning Statutes into Strategy

For Kat, regulation serves as a framework for building smarter and more ethical models. She interprets CMS guidance and OIG rules as levers for innovation, using them to advance integrity and accountability. With the CMS V28 risk adjustment model, Alvarez refined coding practices, strengthened clinical documentation, and structured risk frameworks that reward accuracy and elevate standards of care. In addressing RADV audits, she crafted strategies that protect stakeholders while keeping patient outcomes at the forefront. She aligns compliance, cost, and care in equal measure. Her current work as a contributor to the CMS IDea Challenge, an initiative focused on strengthening the foundation of trust in our system, further echoes her commitment to advancing regulations in ways that unlock innovation while safeguarding the integrity of care.

Her interpretive approach brings discipline and vision to every challenge. She engages stakeholders to redesign workflows that meet regulatory requirements and enhance the patient experience. Each policy becomes a mechanism to strengthen accountability and operational precision, shaping a system that is both compliant and humane.

Innovation Built Within Boundaries

At KATALYST & CO, this interpretive approach is carried into every project. Kat has integrated predictive analytics and AI-driven tools into care models, with safeguards that ensure interventions remain clinician-led and ethically sound. For example, AI flags in chronic disease management are connected to human-led actions that improve patient care. The result is a model that benefits from technology while preserving accountability and clinical integrity.

Staffing and infrastructure provide another example of her philosophy in action. By leveraging offshore BPO operations in Latin America, Asia, and Eastern Europe, KATALYST & CO extends capacity for health plans and providers. These expansions are carefully designed to meet data security, licensure, and jurisdictional requirements, ensuring that global reach is paired with local compliance. It is a system that balances scale with responsibility.

The Art of Influence Through Alignment

Kat often describes her role as translating complexity into clarity. Whether she is working with payers, providers, or investors, she builds consensus by grounding ambitious strategies in the language of statute. Value-based care models, utilization management programs, and clinical frameworks are designed to prove compliant ROI for stakeholders while maintaining patient focus.

Her approach begins with people. In integrations, partnerships, and platform builds, she respects legacy strengths, listens to frontline voices, and creates systems that are not only efficient but also trusted. This ensures that compliance does not feel like restriction, but like a structure that supports innovation and adoption.

Redefining the Future of Compliance and Care

KATALYST & CO is scaling with $10M in initial funding, expanded international operations, and a growing advisory portfolio. Under Kat’s leadership, the firm is showing how regulation can be a foundation for both innovation and durability. She demonstrates that lasting progress in healthcare is achieved by leaders who know how to design systems that are bold, ethical, and deeply human.

By approaching regulation as a guide rather than a limitation, Kat Alvarez is building models that prove compliance and innovation can move forward together. Her formula ensures that the future of healthcare is shaped not only by ambition, but also by trust and responsibility.